Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: An update. Part I: Synthesis, receptors and role of leukotrienes in asthma

Pharmacological Research

Volumn 40, Issue 1, 1999, Pages 3-13

  Devillier, Philippe ^a   Baccard, Nathalie ^a   Advenier, Charles ^b  

^a Ho a5pital Maison Blanche Ctr H   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Asthma; Bronchoconstriction; Inflammation; Leukotriene receptors; Leukotrienes

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; LEUKOTRIENE; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE;

AIRWAY OBSTRUCTION; ASTHMA; EDEMA; EOSINOPHIL; HUMAN; INFLAMMATORY CELL; PRIORITY JOURNAL; RECEPTOR BINDING; RESPIRATORY TRACT MUCOSA; REVIEW; SMOOTH MUSCLE CONTRACTION; TRACHEA MUSCLE;

EID: 0033052355     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1998.0458     Document Type: Article

References (117)

1. Holgate S T. Asthma: past, present and future. Eur Respir J. 6:1993;1507-1520.
2. McFadden E R, Gilbert I A. Asthma. New Engl J Med. 327:1992;1928-1937.
3. Barnes P J. Inhaled glucocorticoids for asthma. New Engl J Med. 332:1995;868-875.
4. Djukanovic R, Wilson J W, Britten K M, Wilson S J, Walls A F, Roche W R, Howarth P H, Holgate S T. Effect of inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis. 145:1992;669-674.
5. Thorax. 48:1993.
6. Cockcroft D W. Practical issues in asthma management: correct use of inhalation devices. Ann Allergy. 71:1993;83-84.
7. De Blic J. Thérapeutiques inhalées dans l'asthme de l'enfant. Presse Med. 24:1995;1724-1726.
8. Cochrane G M. Compliance in asthma: a European perspective. Eur Resp Rev. 26:1995;116-119.
9. Taggart V S. Implementation of the guidelines: a patient's perspective. Eur Resp Rev. 26:1995;112-115.
10. Simmons M S, Nides M A, Rand C S, Wise R A, Tashkin D P. Trends in compliance with bronchodilator inhaler use between follow-up visits in a clinical trial. Chest. 109:1996;963-968.
11. Allen D B, Mullen M L, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol. 93:1994;967-976.
12. Thomson N C. Nedocromil sodium: an overview. Respir Med. 83:1989;269-276.
13. Fabbri L M, Piatella M, Caramori G, Ciaccia A. Oral vs inhaled asthma therapy. Drugs. 1996;20-28.
14. Hay D WP, Torphy T J, Undem B J. Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol Sci. 16:1995;304-309.
15. Chung K F. Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Eur Respir J. 8:1995;1203-1213.
16. Borgeat P, Samuelsson B. Arachidonic acid metabolism in polymorphonuclear leukocytes: unstable intermediate in formation of dihydroxyacids. Proc Natl Acad Sci USA. 76:1979;3213-3217.
17. Holtzman M J. Arachidonic acid metabolism. Am Rev Respir Dis. 143:1991;188-203.
18. In K H, Asano K, Beier D, Grobholz J, Finn P W, Silverman E K, Silverman E S, Collins T, Fischer A R, Keith T P, Serino K, Kim S W, De Sanctis G T, Yandava C, Pillari A, Rubin P, Kemp J, Israel E, Busse W, Ledford D, Murray J J, Segal A, Tinkleman D, Drazen J. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest. 99:1997;1130-1137.
19. 4synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet. 350:1997;1599-1600.
20. 4synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest. 101:1998;834-846.
21. 4in different human tissues is attributable to distinct membrane bound biosynthetic enzymes. J Biol Chem. 272:1997;10182-10187.
22. Henderson W R. The role of leukotrienes in inflammation. Ann Intern Med. 121:1994;684-697.
23. O'Byrne P M. Leukotrienes in the pathogenesis of asthma. Chest. 111:1997.
24. Lewis R A, Austen F, Soberman R J. Leukotrienes and others products of the 5-lipoxygenase pathway. N Engl J Med. 323:1990;6452-6655.
25. Woods J W, Evans J F, Ethier D, Scott S, Vickers P J, Hearn L, Heiben J A, Charleson S, Singer I I. 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J Exp Med. 178:1993;1935-1946.
26. Ford-Hutchinson A W. FLAP: a novel drug target for inhibiting the synthesis of leukotriene. Trends Pharmacol Sci. 12:1991;68-70.
27. Mancini J A, Abramovitz M, Cox M E, Wong E, Charleson S, Perrier H, Wang Z, Prasit P, Vickers P J. 5-lipoxygenase-activating protein is an arachidonate binding protein. FEBS Lett. 318:1993;277-281.
28. Brock T G, McNish R W, Bailie M B, Peters-Golden M. Rapid import of cytosolic 5-lipoxygenase into the nucleus of neutrophils after in vivo recruitment and in vitro adherence. J Biol Chem. 272:1997;8276-8280.
29. Peters-Golden M. Molecular mechanisms of leukotriene synthesis: the changing paradigm. Clin Exp Allergy. 28:1998;1059-1065.
30. 4-synthase. Biochem Pharmacol. 53:1997;905-908.
31. 4synthase. Can J Physiol Pharmacol. 75:1997;1212-1219.
32. Kumlin M. Measurements of leukotrienes in the urine: strategies and applications. Allergy. 52:1997;124-135.
33. Murphy, R, C, Wheelan, P, Metabolism of leukotrienes in vitro and in vivo, Holgate, SDahlén SE, SRS-A to leukotrienes the dawning of a new treatment, London: Blackwell Sci. Publishers, 1997, 101, 20.
34. 4that mediates chemotaxis. Nature. 387:1997;620-624.
35. Owman C, Sabirsh A, Boketoft A, Olde B. Leukotriene B4 is the functional ligand binding to and activating the cloned chemoattractant receptor, CMKRL1. Biochem Biophys Res Commun. 240:1997;162-166.
36. Labat C, Ortiz J L, Norel X, Gorenne I, Verley J, Abram S T, Cuthbert N J, Tudhope S R, Normann P, Gardiner P, Brink C. A second cysteinyl leukotriene receptor in human lung. J Pharm Exp Ther. 263:1992;800-805.
37. Dahlén, S, E, Leukotriene receptors and their antagonists, Holgate, SDahlén SE, SRS-A to leukotrienes the dawning of a new treatment, London: Blackwell Sci. publishers, 1997, 155, 69.
38. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opinion Lipidol. 8:1997;159-166.
39. Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker M G, Wahli W. Fatty acids, eiscosamoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrin. 11:1997;779-791.
40. 4pathway to inflammation control. Nature. 384:1997;39-43.
41. Lee S S, Pineau T, Drago J, Lee E J, Owens J W, Kroetz D L, Fernandez Salguero P M, Westphal H, Gonzalez F J. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol. 15:1995;3012-3022.
42. 4receptor antagonist devoid of peroxisomal enzyme induction. Bioorg Med Chem Lett. 5:1995;283-288.
43. 4-antagonist compound LY171883 on B6C3F1 mice. Fund Appl Toxicol. 15:1990;676-682.
44. 4antagonist compound LY171883 on fisher 344 rats and rhesus monkeys. Fund Appl Toxicol. 14:1990;123-130.
45. 4antagonist. Fund Appl Toxicol. 23:1994;298-303.
46. Sanders J E, Eigenberg D A, Bracht L J, Wang W R, Van Zwieten M J. Thyroid and liver trophic changes in rats secondary to liver microsomal enzyme induction caused by an experimental leukotriene antagonist (L-649,923). Toxicol Appl Pharmacol. 95:1988;378-387.
47. Foxworthy P S, Perry D N, Hoover D M, Eacho P I. Changes in hepatic lipid metabolism associated with lipid accumulation and its reversal in rats given the peroxisome proliferator LY171883. Fund Appl Toxicol. 106:1990;375-383.
48. 4transfer. Trends Pharmacol Sci. 14:1993;351-354.
49. Sampson A P, Thomas R U, Costello J F, Piper P J. Enhanced leukotriene synthesis in leukocytes of atopic and asthmatic subjects. Br J Clin Pharmac. 33:1992;423-430.
50. Koshino T, Takano S, Houjo T, Sano Y, Kudo K, Kihara H, Kitani S, Takaishi T, Hirai K, Ito K, Morita Y. Expression of 5-lipoxygenase and 5-lipoxygenase-activating protein mRNAs in the peripheral blood leukocytes of asthmatics. Biochem Biophys Res Commun. 247:1998;510-513.
51. Lam S, Chan H, Leriche J C, Chan-Yeung M, Salari H. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol. 81:1988;711-717.
52. 4in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis. 142:1990;112-119.
53. Wenzel S E, Westcott J Y, Larsen G L. Bronchoalveolar lavage fluid mediator levels 5 min after allergen challenge in atopic subjects with asthma: relationship to the development of late asthmatic responses. J Allergy Clin Immunol. 87:1991;540-548.
54. Chan-Yeung M, Chan H, Tse K S, Salari H, Lam S. Histamine and leukotrienes release in bronchoalveolar fluid during plicatic acid-induced bronchoconstriction. J Allergy Clin Immunol. 84:1989;762-768.
55. Sladek K, Dworski R, Soja J, Sheller J R, Nizankowska E, Oates J A, Szczeklik A. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med. 149:1994;940-946.
56. Szczeklik A, Sladek K, Dworski R, Nizankowska E, Soja J, Sheller J, Oates J. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am J Respir Crit Care Med. 154:1996;1608-1614.
57. Pliss L B, Ingenito E P, Ingram R H, Pichurko B. Assessment of bronchoalveolar cells and mediator response to isocapnic hyperpnea in asthma. Am Rev Respir Dis. 142:1990;73-78.
58. Clin Exp Allergy. 26:1996;903-908.
59. Kowalski M L, Sliwinska-Kowalska M, Igarashi Y, White M V, Wojciechowska B, Brayton P, Kaulbach H, Rozniecki J, Kaliner M A. Nasal secretions in response to acetylsalicylic acid. J Allergy Clin Immunol. 91:1993;580-598.
60. Picado C, Ramis I, Rosellò J, Prat J, Bulbena O, Plaza V, Montserrat J M, Gelpí E. Release of peptide leukotrienes into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am Rev Respir Dis. 145:1992;65-69.
61. Ferreri N R, Howland W C, Stevenson D D, Spielberg H L. Release of leukotrienes, prostaglandins and histamine into nasal secretions of aspirin-sensitive asthmatic during reaction to aspirin. Am Rev Respir Dis. 137:1988;847-854.
62. 4and histamine excretion rates in normal subjects and patients with mild-to-moderate asthma. J Allergy Clin Immunol. 96:1995;643-651.
63. Wenzel S E, Trudeau J B, Kaminsky D A, Cohn J, Martin R J, Westcott J Y. Effect of 5-lipoxygenase inhibitor on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med. 152:1995;897-905.
64. 4and histamine in asthmatics. Am Rev Respir Dis. 146:1992;96-103.
65. 4concentrations increase after aspirin challenge in aspirin-sensitive asthmatic patients. Am Rev Respir Dis. 143:1991;1025-1029.
66. 4in the assessment of nocturnal asthma. J Allergy Clin Immunol. 97:1996;735-741.
67. 4after antigen challenge and in acute asthma and allergic rhinitis. Lancet. I:1989;584-588.
68. 4levels following allergen and exercise challenge in bronchial asthma. Am Rev Respir Dis. 144:1991;1411-1413.
69. 4excretion in exercise-induced asthma. J Appl Physiol. 73:1992;743-748.
70. 4after exercise challenge in children with asthma. 1992;. p. 1111-9.
71. 4excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med. 153:1996;572-575.
72. Ellis J L, Undem B J. Role of cysteinyl leukotrienes and histamine in mediating intrinsic tone in isolated human bronchi. Am J Respir Crit Care Med. 149:1994;118-121.
73. Watson N, Magnussen H, Rabe K F. Inherent tone of human bronchus: role of eicosanoids and the epithelium. Br J Pharmacol. 121:1997;1099-1104.
74. 4. Proc Natl Acad Sci USA. 80:1983;1712-1716.
75. Drazen E M, Austen K F. Leukotrienes and airway responses. Am Rev Respir Dis. 136:1987;985-998.
76. Bolla M, Caruso P, Giossi M, Folco G, Civelli M, Sala A. Comparative analysis of isolated human bronchi contraction and biosynthesis of cysteinyl leukotrienes using a direct 5-lipoxygenase inhibitor. Biochem Pharmacol. 54:1997;437-442.
77. Björck T, Dahlén S E. Leukotrienes and histamine mediate IgE-dependent contractions of human bronchi: pharmacological evidence obtained with tissues from asthmatic and non-asthmatic subjects. Pulm Pharmacol. 6:1993;87-96.
78. Arm J P, Lee T H. Sulphidopeptide leukotrienes in asthma. Clin Sci. 84:1993;501-510.
79. 4, methacholine and histamine. Am Rev Respir Dis. 142:1990;1112-1118.
80. Garcia J GN, Noonan T C, Jubiz W, Malik A B. Leukotrienes and the pulmonary microcirculation. Am Rev Respir Dis. 136:1987;161-169.
81. Gorenne I, Norel X, Brink C. Cysteinyl leukotriene receptors in the human lung: what's new. Trends Pharmacol Sci. 17:1996;342-345.
82. Voelkel N F, Tuder R M, Wade K, Höper M, Lepley R A, Goulet J L, Koller B H, Fitzpatrick F. Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. J Clin Invest. 97:1996;2991-2998.
83. 4: endothelial contraction. Am J Pathol. 126:1987;19-24.
84. 4and histamine-induced cutaneous vascular reactions in man. J Allergy Clin Immunol. 87:1991;93-98.
85. Hay D WP. Pharmacology of leukotriene receptor antagonists. Chest. 111:1997.
86. 4receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody. Am J Respir Crit Care Med. 154:1996;850-857.
87. 4and granulocytic infiltration into asthmatic airways. Lancet. 341:1993;989-990.
88. 4effects on human eosinophil and neutrophil motility in vitro. J Leukoc Biol. 55:1994;183-191.
89. Pedersen K E, Bochner B S, Undem B J. Cysteinyl leukotrienes induce P-selectin expression in human endothelial cells via a non-CysLT1 receptor-mediated mechanism. J Pharmacol Exp Ther. 281:1997;655-662.
90. Liu Y C, Khawaja A M, Rogers D F. Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast on tracheal mucus secretion in ovalbumin-sensitized guinea-pigs in vitro. Br J Pharmacol. 124:1998;563-571.
91. Wanner A, Salathé M, O'Riordan T G. Mucociliary clearance in the airways. Am J Respir Crit Care Med. 154:1996;1868-1902.
92. 4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis. 126:1982;449-451.
93. 4on ciliary activity in human, guinea-pig and rat respiratory mucosa. Pulm Pharmacol. 9:1996;231-238.
94. 4increase the ciliary beat frequency in human upper airway mucosa in vitro. Otolaryngol Head Neck Surg. 118:1998;472-477.
95. Ahmed T, Greenblatt D W, Birch S, Marchette B, Wanner A. Abnormal mucociliary transport in allergic patients with antigen-induced bronchospasm: role of slow reacting substance of anaphylaxis. Am Rev Respir Dis. 124:1981;110-114.
96. 4induced vascular smooth muscle cell proliferation: a possible role in myointimal hyperplasia. Thromb Haemost. 76:1996;99-104.
97. 4in allergen-induced increases in airway smooth muscle in the rat. Am Rev Respir Dis. 148:1993;413-417.
98. Sterk P J. Improving asthma treatment: the physiologic message. Eur Respir J. 7:1994;220-222.
99. James A L, Paré P D, Hogg J C. The mechanics of airway narrowing in asthma. Am Rev Respir Dis. 139:1989;242-246.
100. 4on canine bronchial smooth muscle. Am J Physiol. 266:1994.
101. 4-induced histamine hyperresponsiveness in guinea-pig tracheal and human bronchial smooth muscle, in vitro. Br J Pharmacol. 104:1991;859-866.
102. Ellis JL, Undem BJ. Role of peptidoleukotrienes in capsaicin-sensitive sensory fibre-mediated responses in guinea-pig airways. J Physiol. 436:1991;469-484.
103. 4and substance P from guinea pig lungs. Am J Physiol. 261:1991.
104. McAlexander M A, Myers A C, Undem B J. Inhibition of 5-lipoxygenase diminishes neurally evoked tachynergic contraction of guinea pig isolated airway. J Pharmacol Exp Ther. 285:1998;602-607.
105. 4and antigen-induced contraction of guinea pig isolated bronchus. J Pharmacol Exp Ther. 283:1997;1102-1109.
106. Ishida K, Thomson R J, Schellenberg R R. Role of leukotrienes in airway hyperresponsiveness in guinea-pigs. Br J Pharmacol. 108:1993;700-704.
107. Sato T, Iwama T, Shikada K, Tanaka S. Airway hyperresponsiveness to acetylcholine induced by aerosolized arachidonic acid metabolites in guinea-pigs. Clin Exp Allergy. 26:1996;957-963.
108. 4in guinea-pigs. Clin Exp Allergy. 24:1994;960,-8.
109. 4receptor antagonism reduces airway hyperresponsiveness in monkeys. Pulm Pharmacol. 7:1994;49-58.
110. Barnes N C. Are leukotrienes involved in causing bronchial hyperresponsiveness. Eur Respir J. 10:1997;2701-2703.
111. 4in asthmatic subjects. Br J Clin Pharmac. 39:1995;119-123.
112. Sehmi R, Wardlaw A J, Cromwell O, Kurihawa K, Waltmann K, Kay A B. Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects. Blood. 79:1992.
113. 4receptor antagonists - A most discriminating class of antiinflammatory agent. Drugs Fut. 17:1992;819-830.
114. 4receptor antagonist SC-53228 on ozone-induced airway hyperresponsiveness and inflammation in dogs. Am J Respir Care Med. 152:1995;1443-1448.
115. 4antagonism in a primate model of asthma. J Clin Invest. 97:1996;381-387.
116. 4in normal and in asthmatic subjects. Am J Respir Crit Care Med. 155:1997;1789-1792.
117. 4in the human lung. J Clin Invest. 84:1989;1609-1619.